Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 23 Abbreviated New Drug Applications; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on January 15, 2025. The document announced the withdrawal of approval of 23 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of February 14, 2025. The document indicated that FDA was withdrawing approval of the ANDA 209325 for miglustat capsule, 100 milligrams, held by Breckenridge Pharmaceutical, Inc., 15 Massirio Dr., Suite 201, Berlin, CT 06037. Before FDA withdrew the approval of this ANDA, Breckenridge Pharmaceutical, Inc. informed FDA that they did not want the approval of the ANDA withdrawn. Because Breckenridge Pharmaceutical, Inc., timely requested that approval of ANDA 209325 not be withdrawn, the approval is still in effect. This notice corrects this error.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 67 (Wednesday, April 9, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 67 (Wednesday, April 9, 2025)]
[Notices]
[Page 15253]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-06052]
[[Page 15253]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-5964]
Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of
23 Abbreviated New Drug Applications; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register on January 15, 2025. The document
announced the withdrawal of approval of 23 abbreviated new drug
applications (ANDAs) from multiple applicants, withdrawn as of February
14, 2025. The document indicated that FDA was withdrawing approval of
the ANDA 209325 for miglustat capsule, 100 milligrams, held by
Breckenridge Pharmaceutical, Inc., 15 Massirio Dr., Suite 201, Berlin,
CT 06037. Before FDA withdrew the approval of this ANDA, Breckenridge
Pharmaceutical, Inc. informed FDA that they did not want the approval
of the ANDA withdrawn. Because Breckenridge Pharmaceutical, Inc.,
timely requested that approval of ANDA 209325 not be withdrawn, the
approval is still in effect. This notice corrects this error.
FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 301-
796-3471, <a href="/cdn-cgi/l/email-protection#773a1605031f16593910020e121937111316591f1f0459101801"><span class="__cf_email__" data-cfemail="a6ebc7d4d2cec788e8c1d3dfc3c8e6c0c2c788ceced588c1c9d0">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Correction
In the Federal Register of Wednesday, January 15, 2025 (90 FR
3876), appearing on page 3877 in FR Doc. 2025-00742, the following
correction is made:
On page 3877, in the table, the entry for ANDA 209325 is removed.
Dated: March 31, 2025.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2025-06052 Filed 4-8-25; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.